Passage BIO, Inc.
PASG- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001787297
No open-market purchases or sales by Passage BIO, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $6.82M in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in Passage BIO, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 102
- 0 vs. Q3 2021
- Shares held
- 43.7M
- +1.72M (+4.1%) vs. Q3 2021
- Total value
- $277.7M
- −$140.8M (−33.6%) vs. Q3 2021
- New holders
- 19
- 41 more added
- Sold out
- 19
- 23 more reduced
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PASG on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 29 | $6.82M |
| Q1 2026 | 35 | $13.8M |
| Q4 2025 | 30 | $18.6M |
| Q3 2025 | 32 | $13.2M |
| Q2 2025 | 41 | $13.0M |
| Q1 2025 | 42 | $12.8M |
| Q4 2024 | 46 | $21.6M |
| Q3 2024 | 45 | $27.1M |
| Q2 2024 | 45 | $32.0M |
| Q1 2024 | 51 | $54.4M |
| Q4 2023 | 52 | $33.1M |
| Q3 2023 | 51 | $21.3M |
| Q2 2023 | 56 | $31.4M |
| Q1 2023 | 59 | $34.0M |
| Q4 2022 | 68 | $51.6M |
| Q3 2022 | 76 | $49.3M |
| Q2 2022 | 87 | $99.6M |
| Q1 2022 | 110 | $133.2M |
| Q4 2021 | 102 | $277.7M |
| Q3 2021 | 103 | $419.1M |
| Q2 2021 | 102 | $558.8M |
| Q1 2021 | 90 | $786.5M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Passage BIO, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Frazier Management LLC | 5,009,219 | $31.8M | 2.45% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 6,962,899 | $44.2M | 0.57% | 00.0% | Unchanged |
| Boxer Capital, LLC | 0 | $0 | 0.00% | −1,928,315−100.0% | Sold out |
| Vivo Capital, LLC | 0 | $0 | 0.00% | −539,263−100.0% | Sold out |
| Emerald Advisers, LLC | 0 | $0 | 0.00% | −140,699−100.0% | Sold out |
| Alyeska Investment Group, L.P. | 0 | $0 | 0.00% | −138,807−100.0% | Sold out |
| Logos Global Management LP | 0 | $0 | 0.00% | −125,010−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −23,113−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −17,771−100.0% | Sold out |
| Virginia Retirement Systems Et Al | 0 | $0 | 0.00% | −15,900−100.0% | Sold out |
| DekaBank Deutsche Girozentrale | 0 | $0 | 0.00% | −14,300−100.0% | Sold out |
| UBS Asset Management Americas Inc | 0 | $0 | 0.00% | −11,470−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −11,399−100.0% | Sold out |
| Pinz Capital Management, LP | 0 | $0 | 0.00% | −10,800−100.0% | Sold out |
| Principal Financial Group Inc | 0 | $0 | 0.00% | −10,512−100.0% | Sold out |
| Penserra Capital Management LLC | 0 | $0 | 0.00% | −1,235−100.0% | Sold out |
| The PNC Financial Services Group, Inc. | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −587−100.0% | Sold out |
| Quadrant Capital Group LLC | 0 | $0 | 0.00% | −180−100.0% | Sold out |
| Brewin Dolphin Ltd | 0 | $0 | 0.00% | −148−100.0% | Sold out |
| Ellevest, Inc. | 0 | $0 | 0.00% | −8−100.0% | Sold out |
| Marshall Wace North America L.P. | – | – | – | – | Not filed |